{
  "url": "https://openlegislation.uk/medicines-labelling-and-advertising-to-the-public-regulations-1978/schedule-2/part-III",
  "json_url": "https://openlegislation.uk/medicines-labelling-and-advertising-to-the-public-regulations-1978/schedule-2/part-III.json",
  "legislation": "uksi/1978/41",
  "legislation_title": "The Medicines (Labelling and Advertising to the Public) Regulations 1978",
  "legislation_url": "https://openlegislation.uk/medicines-labelling-and-advertising-to-the-public-regulations-1978",
  "path": "schedule/2/part/III",
  "kind": "part",
  "number": "III",
  "heading": null,
  "text": "Column 1\nColumn 2\nColumn 3\nSystem or part of the body\nAdverse conditions of those systems\nPurposes for which advertising is permitted.\n1. The cardio-vascular system.\n(a) All diseases of the myocardium and heart valves, including rheumatic heart disease and coronary artery disease.\nNone.\n(b) Hypertension.\nNone.\n(c) Thrombosis.\nNone.\n(d) Oedema.\nNone.\n(e) Peripheral artery disease.\nTreatment of chilblains.\n(f) Peripheral venous disease.\nTreatment of haemorhoids by relief of symptoms by means of locally effective preparations or stool softening agents and lubricants.\n(g) Retinal vascular change.\nNone.\n2. The blood and the lymphatic system.\n(a) Anaemia.\nProphylactic administration of iron and folic acid to avoid deficiency states in persons with inadequate diet or with increased dietary requirements.\n(b) Bleeding disorders.\nNone.\n(c) Leukaemia or other lymphoproliferative diseases.\nNone.\n3. The endocrine system.\nAny organic or functional condition related to under or over activity of any part of the system.\nWeight reduction dependent upon mechanism involving a reduced calorie or joule intake.\n4. The optical and auditory system.\nAny organic condition affecting sight, hearing or balance.\nRelief of symptoms by means of the local administration of eye preparations.\nRelief of symptoms by means of the local administration of preparations as a solvent for ear wax.\n5. The musculo-skeletal system.\nAny condition referred to as slipped disc, arthritis, osteoarthritis, rheumatoid arthritis or gout.\nSymptomatic relief of muscular pain and stiffness including backache, sciatica, lumbago, fibrositis, rheumatic pain and cramp.\n6. The respiratory system.\nDiseases of the lungs, pleura and bronchial tree.\nTemporary relief of symptoms of hay fever, rhinitis or catarrh.\nRelief of blocked-up sinuses.\nAlleviation of an attack of bronchial asthma.\n7. The teeth and gums.\nPyorrhoea.\nGingivitis.\nPrevention and treatment of gingivitis and prevention of pyorrhoea by means of oral hygiene.",
  "extent": null,
  "status": null,
  "version": "current",
  "annotations": [],
  "outstanding_effects": [],
  "provenance": {
    "source": "legislation.gov.uk",
    "source_url": "https://www.legislation.gov.uk/uksi/1978/41/schedule/2/part/III",
    "retrieved_at": "2026-10-29T19:42:01.140544+00:00"
  },
  "licence": "Open Government Licence v3.0",
  "licence_url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/",
  "attribution": "Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives."
}